Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: Hudson’s Remarks On US ‘First Rights’ Stirs Vaccine Row

Draws Criticism From French Government

Executive Summary

Company clarifies by saying it has production capacity in Europe as well as US and other regions - but follows Hudson's calls for Europe to develop its own BARDA-like agency.

You may also be interested in...



Sanofi Calms France's Fears Over COVID-19 Vaccine Access

Paul Hudson has been at the helm of Sanofi for just nine months, but for the last few days his comments about which country will be first in line for the firm's coronavirus vaccines will have reminded him that the Gallic culture runs deep.

Coronavirus Update: $8bn International Fund For Vaccines Created

Plus: Eli Lilly extends its presence in COVID-19 research with an alliance with China's Junshi Biosciences.

Sanofi Scores In Second-Line Myeloma But Still In Darzalex’s Shadow

The French company believes it has the best-in-class CD38 antibody with new PFS data, but Johnson & Johnson and Genmab’s Darzalex looks set to retain its advantage in multiple myeloma.

Topics

Related Companies

UsernamePublicRestriction

Register

SC142221

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel